"Other tests in development look for different possible markers of disease. Daniel Alkon of the Blanchette Rockefeller Neurosciences Institute in Morgantown, West Virginia and his group have developed a skin test that measures so-called protein kinase C, epsilon (PKCE) levels. PKCE promotes the growth of synapses in the brain and destroys tau protein. It decreases in patients with Alzheimer’s. In clinical trials, Alkon and his group were able to predict which patients would get Alzheimer’s more than 95 percent of the time by measuring PKCE levels in their skin cells. They validated their diagnoses with autopsies years later. But they only studied about 140 patients, and thus will require more findings in later-phase clinical trials. Alkon said he hopes to be able to offer the test to the public in about two years through what is known as a Clinical Laboratory Improvement Amendments-certified lab, and then will seek U.S. Food and Drug Administration approval after that."
Market Data 
Markets 
AI
